Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$57.77

-1.12 (-1.90%)

04:55
11/29/16
11/29
04:55
11/29/16
04:55

Alkermes management to meet with JPMorgan

Meetings to be held in San Francisco/San Mateo on November 28 and in Los Angeles on November 29 hosted by JPMorgan.

  • 29

    Nov

ALKS Alkermes
$57.77

-1.12 (-1.90%)

10/21/16
MSCO
10/21/16
UPGRADE
Target $62
MSCO
Equal Weight
Morgan Stanley ups Alkermes to neutral with $62 target
Morgan Stanley analyst David Risinger upgraded Alkermes to Equal Weight from Underweight after ALKS 5461 succeeded in its third Phase III trial. The analyst raised his price target for the shares to $62 from $45. Risks remain, but an FDA approval can't be ruled out given the unmet need in treatment-resistant depression, Risinger tells investors in a research note. He pegs the approval odds at 50%. Alkermes is trading up 30% to $56.51 in morning trading.
10/24/16
UBSW
10/24/16
NO CHANGE
Target $57
UBSW
Neutral
Alkermes price target raised to $57 from $41 at UBS
UBS analyst Marc Goodman raised his price target for Alkermes to $57 citing the positive Phase III data for ALKS 5461. There is "some chance" of approval based on the current dataset, but the FDA typically requires two positive Phase III studies for approving depression drugs, Goodman tells investors in a research note. The analyst raised the likelihood of approval for ALKS 5461 from 20% to 60%. He keeps a Neutral rating on Alkermes, however, saying the risk/reward is appropriately reflected at current share levels.
11/03/16
LEHM
11/03/16
NO CHANGE
Target $66
LEHM
Overweight
Alkermes Q3 highlighted pipeline advances, says Barclays
Barclays analyst Douglas Tsao believes Alkermes' Q3 earnings report highlighted key advances across its pipeline. The analyst, however, feels that "lumpiness" in Vivitrol gross-to-net over recent quarters "may warrant caution" on the drug's sales trajectory. Tsao still harbors "residual caution" on whether the FDA will accept a single Phase 3 trial for approval of ALKS-5461. Investors though will take comfort in management's reiteration of 2016 guidance, Tsao writes in a post-earnings research note. He keeps an Overweight rating on Alkermes with a $66 price target.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $70
JEFF
Buy
Jefferies says NIH study could be positive for Alkermes' Vivitrol
Jefferies analyst Biren Amin is highlighting a "little known" head-to-head study being conducted at the National Institutes of Health to compare the efficacy of Alkermes' Vivitrol and Indivior's Suboxone. The study enrolled treatment-seeking heroin- and/or prescription opioid-dependent patients admitted into a detox unit, and following a detoxification regimen are randomized to receive Vivitrol or Suboxone treatment for six months, Amin tells investors in a research note. He believes the outcome of the study could have positive implications on Vivitrol's long-term outlook. The analyst does not expect Vivitrol to demonstrate superiority to Suboxone on the primary outcome, but thinks the trial could "illuminate some important differences" and show a trend of improvement for Vivitrol in relapse rate at six months. He points out that Alkermes continues to estimate Vivitrol is currently only capturing 1%-2% market share and sees "significant" room for upside. Data from the study could be seen by year-end 2017 or early 2018, Amin writes. He keeps a Buy rating on Alkermes with a $70 price target.

TODAY'S FREE FLY STORIES

ALDR

Alder Biopharmaceuticals

$18.70

-1 (-5.08%)

15:14
06/27/17
06/27
15:14
06/27/17
15:14
Recommendations
Alder Biopharmaceuticals analyst commentary  »

Concerns driving Alder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CSCO

Cisco

$32.24

0.15 (0.47%)

15:10
06/27/17
06/27
15:10
06/27/17
15:10
Options
Cisco sees short-term put buying ahead of a company event »

Cisco sees short-term put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 12

    Jul

  • 12

    Jul

  • 13

    Jul

  • 16

    Aug

VRX

Valeant

$16.84

-0.24 (-1.41%)

15:05
06/27/17
06/27
15:05
06/27/17
15:05
Recommendations
Valeant analyst commentary  »

Several Valeant products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

CAMP

CalAmp

$19.62

-0.5 (-2.49%)

15:04
06/27/17
06/27
15:04
06/27/17
15:04
Options
CalAmp options imply 15.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

OSUR

OraSure

$15.72

0.17 (1.09%)

14:59
06/27/17
06/27
14:59
06/27/17
14:59
Recommendations
OraSure analyst commentary  »

OraSure price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

GG

Goldcorp

$13.43

-0.24 (-1.76%)

, XRA

Exeter Resource

14:56
06/27/17
06/27
14:56
06/27/17
14:56
Hot Stocks
Goldcorp agrees to acquire all Exeter Resource shares it does not already own »

Goldcorp (GG) announced…

GG

Goldcorp

$13.43

-0.24 (-1.76%)

XRA

Exeter Resource

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

KBH

KB Home

$23.04

0.26 (1.14%)

14:49
06/27/17
06/27
14:49
06/27/17
14:49
Options
KB Home options imply 6.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

CMCSA

Comcast

$39.59

0.09 (0.23%)

, CMCSK

Comcast

14:41
06/27/17
06/27
14:41
06/27/17
14:41
Periodicals
NBC Sports to offer Premier League streaming package, Recode says »

NBCUniversal's NBC…

CMCSA

Comcast

$39.59

0.09 (0.23%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CF

CF Industries

$27.08

-0.33 (-1.20%)

14:30
06/27/17
06/27
14:30
06/27/17
14:30
Options
CF sees call buying »

CF sees call buying. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:30
06/27/17
06/27
14:30
06/27/17
14:30
General news
Yellen reiterated the Fed's commitment to price stability »

Yellen reiterated the…

MLHR

Herman Miller

$29.50

0.1 (0.34%)

14:27
06/27/17
06/27
14:27
06/27/17
14:27
Initiation
Herman Miller initiated  »

Herman Miller initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

DECK

Deckers Brands

$67.76

0.82 (1.23%)

14:26
06/27/17
06/27
14:26
06/27/17
14:26
Hot Stocks
Marcato confirms letter to Deckers, says prepared to seek board ouster »

Marcato Capital, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$27.67

3.43 (14.15%)

14:25
06/27/17
06/27
14:25
06/27/17
14:25
Options
Avis Budget call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DECK

Deckers Brands

$67.54

0.6018 (0.90%)

14:20
06/27/17
06/27
14:20
06/27/17
14:20
Periodicals
Marcato threatens proxy fight at Deckers Brands, CNBC reports »

CNBC's Leslie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
06/27/17
06/27
14:17
06/27/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$242.12

-1.1728 (-0.48%)

, SPX

S&P 500

14:16
06/27/17
06/27
14:16
06/27/17
14:16
Technical Analysis
Technical View: S&P 500 takes out channel low »

The S&P 500 (SPX) has…

SPY

SPDR S&P 500 ETF Trust

$242.12

-1.1728 (-0.48%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DECK

Deckers Brands

$67.53

0.59 (0.88%)

14:16
06/27/17
06/27
14:16
06/27/17
14:16
Periodicals
Marcato threatens proxy fight at Deckers Brands, CNBC reports 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/27/17
06/27
14:16
06/27/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$34.59

-0.565 (-1.61%)

14:15
06/27/17
06/27
14:15
06/27/17
14:15
Options
AstraZeneca put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

14:10
06/27/17
06/27
14:10
06/27/17
14:10
General news
Treasury Action: Fed chair Yellen hasn't said anything on the policy path »

Treasury Action: Fed…

AIII

ACRE Realty Investors

14:09
06/27/17
06/27
14:09
06/27/17
14:09
Hot Stocks
Breaking Hot Stocks news story on ACRE Realty Investors »

ACRE Realty Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDG

TransDigm

$264.99

-3.26 (-1.22%)

14:05
06/27/17
06/27
14:05
06/27/17
14:05
Hot Stocks
TransDigm slips after Capitol Forum says DLA confirms active probe »

Shares of TransDigm are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENFC

Entegra Financial

$23.40

0.25 (1.08%)

14:04
06/27/17
06/27
14:04
06/27/17
14:04
Downgrade
Entegra Financial rating change  »

Entegra Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIII

ACRE Realty Investors

14:01
06/27/17
06/27
14:01
06/27/17
14:01
Hot Stocks
ACRE Realty Investors announces board approval of dissolution »

ACRE Realty Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.72

-0.4349 (-1.14%)

13:55
06/27/17
06/27
13:55
06/27/17
13:55
Options
AT&T put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.